Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations

NEXT STORY
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
PREV STORY
Anaqua Lands Patent Management Deal with the U.S. Army Medical Research and Development Command
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Paratek, U.S. Department of Defense Enter Research Agreement to Study Omadacycline Against Biodefense Pathogens

BOSTON, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today it ...

author_avatar
NASDAQ Market News

Press release: The operations of Puistosairaalan Silmälääkärit Oy and Jyväskylän Silmätutkimuslaboratorio Oy to become part of Terveystalo

On October 31, Terveystalo signed a contract on acquiring the operations of Puistosairaalan Silmälääkärit ...

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2019 First Quarter Results

First quarter 2019 revenue increased to $10.3 million with gross margin of 33%, net ...

author_avatar
NASDAQ Market News